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Abstract
The legal risks associated with health research involving human subjects have been highlighted
recently by a number of lawsuits launched against those involved in conducting and evaluating the
research. Some of these cases have been fully addressed by the legal system, resulting in judgments
that provide some guidance. The vast majority of cases have either settled before going to trial, or
have not yet been addressed by the courts, leaving us to wonder what might have been and what
guidance future cases may bring. What is striking about the lawsuits that have been commenced is
the broad range of individuals/institutions that are named as defendants and the broad range of
allegations that are made. The research community should take this early experience as a warning
and should reflect carefully on practices where research involving human subjects is concerned.
The legal risks associated with health research involving
human subjects have been highlighted recently by a
number of lawsuits launched against those involved in
conducting and evaluating the research [1]. Some of these
cases have been fully addressed by the legal system, result-
ing in judgments that provide some guidance. The vast
majority of cases have either settled before going to trial,
or have not yet been addressed by the courts, leaving us to
wonder what might have been and what guidance future
cases may bring. What is striking about the lawsuits that
have been commenced is the broad range of individuals/
institutions that are named as defendants and the broad
range of allegations that are made.
Plaintiffs cast a wide net: the range of defendants 
named
A review of recent Canadian and American cases demon-
strates that in commencing lawsuits over alleged research
misconduct, plaintiffs cast a wide net, naming as defend-
ants anyone who had anything to do with the research in
question. Named defendants have included the research-
ers, the research ethics committee/board/institutional
review board (REC) that approved the research and its
individual members, as well as bioethicists who consulted
on the research project.
For example, in Gelsinger  v. Trustees of the University of
Pennsylvania  [2], an eighteen year-old who had volun-
teered to participate in a corrective gene study died during
the course of the study. In that case, the trustees of the uni-
versity and two hospitals affiliated with the research, the
investigators, the company that sponsored the research,
the former medical school dean and a bioethicist, were all
originally named as defendants on the bases (among oth-
ers) of wrongful death, assault and battery linked to a lack
of informed consent, and common law fraud/misrepre-
sentation linked to the informed consent process. The
case settled for an undisclosed amount [3].
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In Robertson v. McGee [4], the REC had approved a proto-
col for a Phase I study of a cancer vaccine. Many of the
patients who enrolled in the study had advanced disease,
were unresponsive to standard therapies and had very
poor prognoses. According to news reports, 94 subjects
received the vaccine and 26 died during the study,
although the deaths were not attributed to the vaccine
itself [5]. On January 29, 2001, a number of subjects and
subject representatives filed a lawsuit seeking actual and
punitive damages. The Robertson plaintiffs sued the hospi-
tal, the principal investigator, the pharmaceutical spon-
sor, a top university official, the individual members of
the REC, and the university bioethicist who consulted
with the REC. The issues in this case were never decided by
the court because the court held that it did not have juris-
diction over the allegations made in the complaint and
dismissed the case.
In the case of Weiss v. Solomon [6], a research subject suf-
fered a cardiac arrest and died after undergoing a fluores-
cein angiogram as part of a research study. The deceased's
family sued the principal investigator, the hospital and a
physician who referred one of his patients to the study.
The Court hearing the case ultimately found liability
against the primary investigator and hospital only. Inter-
estingly, the liability against the hospital was based in part
upon the fact that the hospital's REC had approved the
research protocol and the consent form which was deter-
mined by the Court to be deficient.
All of these cases demonstrate that plaintiffs cast a wide
net when deciding whom to name as defendants in cases
where research goes wrong. It is possible for almost any-
one involved in a research project, no matter how
remotely connected, to be named in legal proceedings if
something goes wrong. Unfortunately, there are not
enough decided cases to predict with any degree of cer-
tainty how far the courts in Canada and the United States
(U.S.) will be prepared to go in attributing fault in
research negligence cases to those that have less than a
direct connection to the injuries that have been sustained.
Broad range of allegations made
A review of the lawsuits that have been commenced
recently demonstrates that there are a broad range of alle-
gations that can potentially be made against those
involved in research. The allegations are such that it is
open to a plaintiff to sue not only the primary investigator
and others directly involved in the research but also those
with a much less tangible relationship to the research sub-
ject. What follows is a brief overview of some of the more
common allegations that have been made and what, if
anything, the courts have said about these allegations.
Deficiencies in the consent process
It is perhaps obvious for most health care professionals
that liability will arise where research is conducted with-
out informed consent from the subjects (or their substi-
tute decision makers) being obtained. What may be less
known is that it appears from existing case law as though
the standard for obtaining informed consent in the
research context is higher than in the therapeutic context.
The other interesting development has been that it
appears that courts may be willing to hold a hospital
responsible where the informed consent form approved
by the REC of the Hospital is determined to be less than
adequate.
In the Weiss case for example, the Quebec Superior Court
found that the duty to inform in matters relating to purely
scientific experimentation is the most exacting possible
and includes the disclosure of all known risks including
those which are rare or remote, especially if they may
entail grave consequences [7]. This would suggest a stand-
ard that is higher than the standard for consent to treat-
ment which requires that only material risks be disclosed.
In addition, the court in Weiss found that the hospital was
liable and attributed some of that liability to the fact that
the hospital's REC failed to ensure that the consent form
used for the research was appropriate.
Failure to follow laws, regulations, policies, procedures and 
guidelines
Some of the recent lawsuits have alleged that the defend-
ants failed to follow applicable laws, regulations, policies,
procedures and/or guidelines. If these allegations can be
proven, it is likely that liability will follow, as a failure to
comply with applicable laws, regulations, policies, proce-
dures and/or guidelines will likely be interpreted by the
courts as a clear sign that the defendants failed to meet the
standard of care.
Government initiated legal proceedings
In addition to being sued by research subjects who allege
being injured by their participation in a study, there is also
a possibility that the researchers and institutions involved
in health research involving human subjects will face legal
battles with governmental bodies/agencies with jurisdic-
tion over research. In the U.S., such bodies have imposed
drastic sanctions where there is evidence of research mis-
conduct.
The defendants in the Gelsinger case not only settled with
the plaintiffs, they also settled with the U.S. government
in a separate civil action commenced by the government
on the basis of breach of the False Claims Act [8]. The set-
tlement resulted in a total of over one million dollars in
payments to the government by the institutions involvedBMC Medical Ethics 2005, 6:4 http://www.biomedcentral.com/1472-6939/6/4
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in the research as well as restrictive controls being placed
on three investigators involved in the research with
respect to their future clinical research activities [9].
Conflict of Interest
In the case of Gelsinger, the complaint alleged, among
other things, that the university was to receive an owner-
ship stake in Genovo (the sponsor) in lieu of funding of
the gene transfer research program and that the University
and various physicians associated with the research pro-
gram had substantial financial and equity interests with
respect to the vectors employed in the research [10]. The
extent of these financial interests were not disclosed to
Jesse Gelsinger before he made his decision to participate
in the research as a subject [11]. If this case had not settled
and instead proceeded to a trial, one of the key issues
would have been the circumstances under which an
undisclosed conflict of interest will result in liability for
the individual(s) and/or entities who are in the conflict
position and whether other parties who know of the con-
flict or who ought reasonably to know about the conflict
and are in a position of authority have a legal obligation
to intervene to prevent the research from proceeding on
the basis of the conflict. The existence of an undisclosed
conflict of interest may also put a plaintiff in the position
of being able to argue that the consent given was not truly
informed.
Lawsuits based on principles of international 
human rights
In the case of Abdullahi v. Pfizer, Inc. [12], Pfizer was the
defendant in a lawsuit that alleged that it improperly
administered an experimental antibiotic to children in
Nigeria during an outbreak of bacterial meningitis, mea-
sles and cholera in Kano, Nigeria. The guardians of certain
of those children instituted an action in the Southern Dis-
trict of New York, alleging violations of the Nuremberg
Code, the Declaration of Helsinki, Article 7 of the Interna-
tional Covenant on Civil and Political Rights, U.S. Food
and Drug Administration's regulations and other norms
of international law. They also asserted that the court had
jurisdiction over the matter under the Alien Torts Claim
Act. This case was sent back to the District Court to deter-
mine whether the U.S. or Nigeria is the appropriate forum
to hear the case [13].
In the Robertson case, several of the causes of action were
derived from international human rights law rather than
standard medical malpractice or tort law, including allega-
tions of breaching the right to be treated with dignity, cit-
ing the Nuremberg Code and Declaration of Helsinki
concerning biomedical research [14].
Conclusion
Admittedly, the number of judgments rendered in
research misconduct lawsuits in North America to date is
small. That being said, experience to date demonstrates
that:
(a) plaintiffs will likely cast a wide net, naming anyone or
any institution that had even the slightest involvement or
connection to the research;
(b) plaintiffs have found a number of different ways to
frame their claims;
(c) the Government may be a potential plaintiff in these
lawsuits; and
(d) the standards applicable in the research context may,
in fact, be higher than those applicable in the therapeutic
treatment context.
The research community should take this early experience
as a warning and should reflect carefully on practices
where research involving human subjects is concerned.
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